Clinical Trial Update: Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD [Phase 2]

View source ↗

Summary

This Phase 2 trial in COPD patients investigates blocking thymic stromal lymphopoietin (TSLP) to reduce airway inflammation and modify epithelial immune respons…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis
• Chronic Obstructive Pulmonary Disease
• Exacerbation of Chronic Obstructive Pulmonary Disease

Snippet

Sponsor: Asger Sverrild | Conditions: COPD, COPD Exacerbation | Phase 2 | Status: RECRUITING